2026-10-11T22:08:50Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33828175 2026-09-16T04:42:36Z category_140 portal_316 item_type_3 month_year_09_2026

Data Sheet 1_Temporal evolution of clinical event risk after primary-prevention ICD implantation: Chagas vs. non-Chagas dilated cardiomyopathy.docx Juan Pablo Guzmán (24960676) Pedro Diaz Uberti (24960679) Camila Rosello (24960682) Maribel Capobianco (24960685) Valeria Piazza (5941970) Fernando Di Tommaso (24960688) Javier Zubiri (24960691) Francisco Toscano (24960694) Cardiology Chagas cardiomyopathy competing risks implantable cardioverter-defibrillator restricted mean survival time risk stratification sudden cardiac death ventricular arrhythmia <p>Chagas cardiomyopathy evolves through progressive myocardial injury that may alter the temporal distribution of arrhythmic risk compared with other dilated substrates. We analysed a two-centre registry of consecutive primary-prevention implantable cardioverter-defibrillator (ICD) recipients in Buenos Aires (2008–2025), excluding cardiomyopathies in which ICD indication is not based on ventricular dysfunction. The final cohort comprised 194 patients: 50 with Chagas cardiomyopathy (26%), 83 with ischaemic (43%) and 61 with non-ischaemic dilated cardiomyopathy (31%). Median LVEF was 30% in both groups. The primary endpoint was a composite of appropriate ICD therapy, adjudicated on stored electrograms, or all-cause death. Pre-planned analyses included multivariable Cox regression, period-specific models split at 5 years, competing-risk regression and restricted mean survival time (RMST). The endpoint occurred in 109 patients. Cumulative incidence was lower in Chagas patients at 1 year (2.1% vs. 12.2%) and 5 years (19.5% vs. 42.4%), and Chagas patients accumulated 682 additional event-free days at 10-year RMST (95% CI: 258–1047; p = 0.001). Chagas cardiomyopathy was associated with lower composite risk (hazard ratio 0.58; 95% CI: 0.37–0.91; p = 0.018), an association confined to the first 5 years (0.35; 0.17–0.75; p = 0.007) and no longer detectable thereafter (0.85; 0.47–1.54; p = 0.587), with 28 and 56 patients at risk at 5 years and 11 and 20 at 10 years. The wide confidence interval and small population at risk in the late period mean that absence of a detectable difference should not be read as evidence of equivalent risk. These findings are hypothesis-generating and require confirmation in larger cohorts.</p> 2026-09-16T04:42:36Z Dataset Dataset 10.3389/fcvm.2026.1950508.s001 https://figshare.com/articles/dataset/Data_Sheet_1_Temporal_evolution_of_clinical_event_risk_after_primary-prevention_ICD_implantation_Chagas_vs_non-Chagas_dilated_cardiomyopathy_docx/33828175 CC BY 4.0